B BRAUN GLUCOSE 5% injection Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

b braun glucose 5% injection

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

B BRAUN GLUCOSE 5% injection Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

b braun glucose 5% injection

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

DNS 500 Intravenous Infusion 0.9% & 5% Τανζανία - Αγγλικά - Tanzania Medicinces & Medical Devices Authority

dns 500 intravenous infusion 0.9% & 5%

alfa pharmaceuticals limited, tanzania - sodium chloride & glucose intravenous infusion bp (0.9% w/v & 5% w/v) - intravenous infusion - 0.9% & 5%

Glucose Intravenous Infusion BP 10 % w/v Τανζανία - Αγγλικά - Tanzania Medicinces & Medical Devices Authority

glucose intravenous infusion bp 10 % w/v

alfa pharmaceuticals limited, tanzania - glucose anhydrous - intravenous infusion - 10 %

PeriOLIMEL N4-600E emulsion for intravenous infusion Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

periolimel n4-600e emulsion for intravenous infusion

baxter healthcare pty ltd - soya oil, quantity: 6 g/l; olive oil, quantity: 24 g/l - injection, intravenous infusion - excipient ingredients: nitrogen; water for injections; sodium hydroxide; egg lecithin; sodium oleate; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Plasma-Lyte 56 in 5% glucose 1000mL injection bag AHB2574 Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

plasma-lyte 56 in 5% glucose 1000ml injection bag ahb2574

baxter healthcare pty ltd - potassium acetate, quantity: 1.28 g/l; sodium chloride, quantity: 2.34 g/l; magnesium acetate tetrahydrate, quantity: 320 mg/l; glucose, quantity: 50 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - plasma-lyte 56 and 5% glucose iv infusion is indicated as a source of water, electrolytes and calories or as an alkalinising agent. plasma-lyte 56 in 5% glucose is indicated as a source of water and electrolytes or as an alkalinising agent.

MOXIFLOXACIN-BAXTER moxifloxacin (as hydrochloride) 400 mg/250 mL solution for intravenous infusion bottle Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

moxifloxacin-baxter moxifloxacin (as hydrochloride) 400 mg/250 ml solution for intravenous infusion bottle

baxter healthcare pty ltd - moxifloxacin hydrochloride, quantity: 1.74 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - moxifloxacin-baxter is indicated for treatment of adults who require initial i.v. therapy for the treatment of infections in the conditions: ? community acquired pneumonia (caused by susceptible organisms) ? acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics moxifloxacin-baxter is indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin-baxter may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

BAXTER POTASSIUM CHLORIDE 40 mmol and 0.9% SODIUM CHLORIDE 100 mL intravenous infusion bag Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

baxter potassium chloride 40 mmol and 0.9% sodium chloride 100 ml intravenous infusion bag

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

OLIMEL N7-960 Emulsion for intravenous infusion Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

olimel n7-960 emulsion for intravenous infusion

baxter healthcare pty ltd - olive oil, quantity: 32 g/l; soya oil, quantity: 8 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; sodium hydroxide; egg lecithin; nitrogen; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

OLIMEL N9-840E Emulsion for intravenous infusion Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

olimel n9-840e emulsion for intravenous infusion

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; water for injections; glycerol; nitrogen; sodium hydroxide - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.